Adjuvants in biopharmaceuticals have been used mainly for human vaccine development to reinforce immunogenicity of vaccines until now. However, it has expanded its applications to other therapeutics such as oncology and treatment for autoimmune diseases, as its specific mechanism of immunity enhancement has been recently identified and immunotherapy to cure the diseases by regulating the human immune system in the limelight. EuBiologics is developing Human Papilloma Virus (HPV) vaccines and EUPOP Life Sciences, a joint venture based in USA, is under development of the vaccine against COVID-19, Respiratory Syncytial Virus (RSV), Herpes Zoster Virus (HZV) and Alzheimer’s Disease with EcML.
| Product Name | EcML |
|---|---|
| Product Purpose | For research and commercial purpose |
| Usage | Immunostimulant |
| Additional Information |
1) Licensing available 2) GMP grade available 3) Price : $200/mg |
| Patent |
1) Bacteria constitutively producing monophosphoryl lipid A, and method for the production of monophosphoryl lipid A using the same(Patent No. : 10-2019331) 2) Bacteria producing hexa-acylated monophosphoryl lipid A, and method for the production of hexa-acylated monophosphoryl lipid A using the same (Patent No.:10-1761348) |
| Research Paper |
1) Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960009/) 2) E. coli-Produced Monophosphoryl Lipid a Significantly Enhances Protective Immunity of Pandemic H1N1 Vaccine (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350214/) |
